NASDAQ:CMMB Chemomab Therapeutics (CMMB) Stock Price, News & Analysis → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free CMMB Stock Alerts $0.67 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.65▼$0.6850-Day Range$0.59▼$0.8652-Week Range$0.42▼$1.89Volume3,373 shsAverage Volume192,952 shsMarket Capitalization$7.40 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Chemomab Therapeutics alerts: Email Address Chemomab Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside944.8% Upside$7.00 Price TargetShort InterestHealthy1.87% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.20) to ($1.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.50 out of 5 stars 3.3 Analyst's Opinion Consensus RatingChemomab Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageChemomab Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.87% of the float of Chemomab Therapeutics has been sold short.Short Interest Ratio / Days to CoverChemomab Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chemomab Therapeutics has recently increased by 14.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldChemomab Therapeutics does not currently pay a dividend.Dividend GrowthChemomab Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CMMB. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Chemomab Therapeutics this week, compared to 1 article on an average week.Search Interest4 people have searched for CMMB on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chemomab Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.91% of the stock of Chemomab Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.05% of the stock of Chemomab Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Chemomab Therapeutics are expected to decrease in the coming year, from ($1.20) to ($1.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chemomab Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chemomab Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChemomab Therapeutics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About Chemomab Therapeutics Stock (NASDAQ:CMMB)Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Read More CMMB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMMB Stock News HeadlinesApril 24, 2024 | globenewswire.comChemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business UpdateApril 18, 2024 | globenewswire.comChemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic SclerosisApril 24, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...April 8, 2024 | finance.yahoo.comChemomab Therapeutics Ltd. (CMMB)April 2, 2024 | globenewswire.comChemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024March 25, 2024 | globenewswire.comChemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing CholangitisMarch 7, 2024 | investorplace.comCMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023March 7, 2024 | finanznachrichten.deChemomab Therapeutics Ltd: Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate UpdateApril 24, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...March 7, 2024 | finance.yahoo.comChemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate UpdateMarch 5, 2024 | prnewswire.comChemomab Therapeutics to Participate in Leerink Global BioPharma ConferenceFebruary 20, 2024 | msn.comBiotech Shares Massively Bid Up Before Opening BellFebruary 20, 2024 | finance.yahoo.comChemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory DiseasesFebruary 20, 2024 | prnewswire.comChemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory DiseasesFebruary 14, 2024 | finance.yahoo.comChemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateFebruary 14, 2024 | prnewswire.comChemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateFebruary 5, 2024 | finance.yahoo.comChemomab Therapeutics to Participate in Upcoming Investor ConferencesJanuary 30, 2024 | finance.yahoo.comChemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing CholangitisJanuary 6, 2024 | benzinga.comChemomab Therapeutics Stock (NASDAQ:CMMB) Dividends: History, Yield and DatesJanuary 3, 2024 | finance.yahoo.comChemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024December 29, 2023 | benzinga.comChemomab Therapeutics Stock (NASDAQ:CMMB) Insider TradesDecember 21, 2023 | benzinga.comChemomab Therapeutics Stock (NASDAQ:CMMB), Analyst Ratings, Price Targets, PredictionsDecember 6, 2023 | msn.comHere's Why Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Is a Great 'Buy the Bottom' Stock NowNovember 16, 2023 | finance.yahoo.comChemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic SclerosisNovember 15, 2023 | markets.businessinsider.comUS Stocks Gain; Producer Prices Fall In OctoberNovember 15, 2023 | markets.businessinsider.comChemomab Reports Fast Track Designation For CM-101 - Quick FactsNovember 15, 2023 | msn.comWhy is Liver Disease Focused Chemomab Stock Trading Higher Today?See More Headlines Receive CMMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CMMB CUSIPN/A CIK1534248 Webwww.chemomab.com Phone972-77-331-0156FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+944.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-114.00% Return on Assets-88.53% Debt Debt-to-Equity RatioN/A Current Ratio4.32 Quick Ratio4.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / Book0.44Miscellaneous Outstanding Shares11,050,000Free Float9,734,000Market Cap$7.40 million OptionableNot Optionable Beta0.36 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Adi Mor George Ph.D. (Age 42)Co-Founder, Chief Scientific Officer, CEO & Executive Director Comp: $435.4kMs. Sigal Fattal CPA (Age 53)M.B.A., Chief Financial Officer Comp: $258kBarbara LindheimConsulting Vice President of Investor & Public Relations, Strategic CommunicationsDr. Matthew B. Frankel M.B.A. (Age 54)M.D., Chief Medical Officer & VP of Drug Development Key CompetitorsPasithea TherapeuticsNASDAQ:KTTAKinetaNASDAQ:KABionomicsNASDAQ:BNOXGraybug VisionNASDAQ:GRAYTFF PharmaceuticalsNASDAQ:TFFPView All Competitors CMMB Stock Analysis - Frequently Asked Questions Should I buy or sell Chemomab Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chemomab Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CMMB shares. View CMMB analyst ratings or view top-rated stocks. What is Chemomab Therapeutics' stock price target for 2024? 3 brokerages have issued 1-year price objectives for Chemomab Therapeutics' shares. Their CMMB share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next year. This suggests a possible upside of 944.8% from the stock's current price. View analysts price targets for CMMB or view top-rated stocks among Wall Street analysts. How have CMMB shares performed in 2024? Chemomab Therapeutics' stock was trading at $0.51 at the beginning of 2024. Since then, CMMB shares have increased by 31.4% and is now trading at $0.67. View the best growth stocks for 2024 here. Are investors shorting Chemomab Therapeutics? Chemomab Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 221,900 shares, an increase of 14.3% from the March 15th total of 194,200 shares. Based on an average trading volume of 224,000 shares, the short-interest ratio is presently 1.0 days. Approximately 1.9% of the shares of the company are sold short. View Chemomab Therapeutics' Short Interest. When is Chemomab Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CMMB earnings forecast. How were Chemomab Therapeutics' earnings last quarter? Chemomab Therapeutics Ltd. (NASDAQ:CMMB) released its quarterly earnings data on Thursday, March, 7th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.14. During the same period in the prior year, the business posted ($0.72) EPS. How do I buy shares of Chemomab Therapeutics? Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CMMB) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPentagon contract could send this $2 AI stock soaringBehind the MarketsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchNew Trump BombshellThe Freeport SocietyThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
